David Martínez‐Cuadrón
A5011914281- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Hematological disorders and diagnostics
- Drug Transport and Resistance Mechanisms
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Fungal Infections and Studies
- Renal and related cancers
- Chemotherapy-induced cardiotoxicity and mitigation
- Single-cell and spatial transcriptomics
- Antifungal resistance and susceptibility
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Cancer therapeutics and mechanisms
Hospital Universitari i Politècnic La Fe
2016-2025
Instituto de Investigación Sanitaria La Fe
2020-2025
Instituto de Salud Carlos III
2017-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
Centro de Investigación Biomédica en Red
2023
Centre Hospitalier Métropole Savoie
2023
Centre Hospitalier Universitaire de Grenoble
2023
Fundación Pethema
2013-2021
Universitat de València
2020
Dana-Farber Cancer Institute
2019
PURPOSE Nucleophosmin 1 ( NPM1) mutations are associated with a favorable prognosis in acute myeloid leukemia (AML) when an internal tandem duplication (ITD) the fms-related tyrosine kinase 3 gene FLT3) is absent FLT3-ITD neg ) or present low allelic ratio ). The 2017 European LeukemiaNet guidelines assume this true regardless of accompanying cytogenetic abnormalities. We investigated validity assumption. METHODS analyzed associations between karyotype and outcome intensively treated...
Abstract The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data 3 700 newly diagnosed ≥70 years. primary objective was to compare overall survival in selected for ( n = 1199) agents 1073). With median follow-up 49.5 months, 10.9 (95% CI: 9.7–11.6) 9.2 months 8.3–10.2)...
Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, outcomes adult sAML in Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were novo 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related (t-AML, 25%), antecedent...
Next-Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established first nationwide diagnostic network seven reference provide standardized NGS studies AML patients. Cross-validation (CV) rounds are regularly performed ensure quality keep updated clinically...
Abstract Background Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior neoplasms (HMA‐sAML) face a dismal prognosis. Methods The authors analyze the characteristics, therapeutic approaches, and outcomes of patients HMA‐sAML from Programa Español para el Tratamiento de Hemopatías Malignas (PETHEMA) registry. Results A total 479 were included, mostly myelodysplastic syndrome (84%). Frontline therapy consisted intensive chemotherapy (IC) in...
There is a limited information available on the clinical characteristics, treatment patterns and outcomes older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 over 60 years of age AML Colombia, using data from RENEHOC-PETHEMA registry, 2009 to 2023. The median at diagnosis was 70 (Range:60–98), 55% were men, 61% had an ECOG < 2, 75.5% de novo AML. FLT3-ITD or NPM1 mutations performed 23.4% 15.6% patients, detected...
Not available.
This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 using conventional PCR (analytical sensitivity 3%) in a nationwide network seven reference laboratories. Between 2019 2021, 1685 adult AML patients at least one centralized sample (NGS or PCR) primary diagnosis relapse/refractory episode were included. During this period, 1288 paired NGS/PCR samples (1094 diagnosis, 103 relapse 88...
The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the VEN a cohort 51 RR-AML patients and evaluated for predictors response overall survival (OS). median age was 68 years, most were at high risk, 61% received ≥2 therapies AML, 49% had hypomethylating agents, ECOG 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery...
Abstract Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared 2022 ELN classification in a real-life cohort 546 intensively 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless classification. Compared with 2017 classification, 14.5% patients changed increasing high-risk group from 44.3%...
Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence 7 SNPs genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences complete remission, though induction death associated to ABCB1 triple variant haplotype (p = .020). related higher nephrotoxicity .016), as well this and allele rs1128503, rs2032582 hepatotoxicity .001; p .049; < .001). Furthermore, ABCC1...
We have evaluated the ex vivo pharmacology of single drugs and drug combinations in malignant cells bone marrow samples from 125 patients with acute myeloid leukemia using a novel automated flow cytometry-based platform (ExviTech). improved previous testing 4 innovations: identifying individual leukemic cells, intact whole blood during incubation, an that escalates reliably data, performing analyses pharmacodynamic population models.Samples were sent 24 hospitals to central laboratory...